Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology, bioanalysis, sequencing (NGS), and 2D and 3D imaging. The company was incorporated in 2008 and is based in Horsholm, Denmark.

Mr. Henrik  Blou

Chief Executive Officer

Mr. Kristian  Borbos

Chief Financial Officer

Ms. Trine Nygaard Hamann

Chief Business Officer

Mr. Jacob  Jelsing

Co-Founder & Chair of the Board

Dr. Niels  Vrang M.D., Ph.D.

Co-Founder & Chief Scientific Officer

Mr. Kristoffer  Rigbolt

Chief Technology Officer

Ms. Margit Bloch Avlund

Head of CSR

Ms. Mads  Axelsen

Chief Medical Officer

Ms. Helle Kirstein Erichsen

Chief Operating Officer

Biotechnologie

Gubra A/S

Gubra A/S Management-Struktur

Informationen zum Management